{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "70-year-old man with a 10 pack-year history of smoking, allergic rhinitis, and bronchial asthma (stable without inhaled corticosteroids). Diagnosed with squamous cell carcinoma of the lung cT4N3M1a stage IVA.",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "10 pack-year history"
            }
          ],
          "allergies": [
            {
              "substance": "allergic rhinitis",
              "reaction": "rhinitis",
              "severity": "unknown"
            }
          ],
          "diagnoses": [
            {
              "code": "C0009402",
              "label": "bronchial asthma",
              "status": "historical"
            },
            {
              "code": "C0007125",
              "label": "Squamous Cell Carcinoma",
              "status": "active"
            },
            {
              "code": "C0242392",
              "label": "lung cancer",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "EGFR mutation negative, PD-L1 < 1%. Patient received two courses of cisplatin (60 mg/m2, day 1) and tegafur/gimeracil/oteracil (TS-1) (120 mg/body, days 1-14) as first-line treatment. No GCSF drugs were used during the initial chemotherapy course, and the eosinophil count did not exceed 300.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0006142",
              "label": "Mutation negative",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "C1306574",
              "value": "< 1",
              "unit": "%",
              "flag": "normal"
            },
            {
              "test": "C0014452",
              "value": null,
              "unit": null,
              "flag": "normal"
            }
          ],
          "medications": [
            {
              "drug": "C0008833",
              "dosage": "60 mg/m2",
              "frequency": "day 1",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C3851920",
              "dosage": "120 mg/body",
              "frequency": "days 1-14",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Primary tumor enlarged, diagnostic evaluation indicates progressive disease (PD).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0032961",
              "label": "Progressive disease",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Atezolizumab (1500 mg every 3 weeks) initiated as second-line therapy, resulting in a partial response (PR).",
        "clinical_data": {
          "medications": [
            {
              "drug": "Atezolizumab",
              "dosage": "1500 mg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": "second-line therapy"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "After 19 cycles of Atezolizumab, the patient developed daily coughing, wheezing, and nocturnal symptoms. Fluticasone furanecarboxylate (200 \u03bcg)/umeclidinium bromide (62.5 \u03bcg)/vilanterol (25 \u03bcg) and a leukotriene receptor antagonist (LTRA) were administered. Eosinophil count increased from approximately 580 to 710. 30 mg prednisolone (PSL) was administered frequently as a burst dose, and continuous PSL was required.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1697610",
              "dosage": "200 \u03bcg/62.5 \u03bcg/25 \u03bcg",
              "frequency": "daily",
              "modality": "inhaled",
              "indication": "coughing, wheezing, and nocturnal symptoms"
            },
            {
              "drug": "leukotriene receptor antagonist",
              "indication": "coughing, wheezing, and nocturnal symptoms"
            },
            {
              "drug": "C0033062",
              "dosage": "30 mg",
              "frequency": "frequently",
              "modality": "oral",
              "indication": "coughing, wheezing, and nocturnal symptoms"
            }
          ],
          "labs": [
            {
              "test": "C0014479",
              "value": "580",
              "unit": "/uL",
              "timestamp": null
            },
            {
              "test": "C0014479",
              "value": "710",
              "unit": "/uL",
              "timestamp": null
            }
          ],
          "HPI": [
            {
              "summary": "coughing, wheezing, and nocturnal symptoms",
              "progression": "daily"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Respiratory function tests showed forced expiratory volume in 1s (FEV1) of 1.59\u2009L, FEV1/forced vital capacity (FVC) of 64.37% and fractional exhaled nitric oxide (FeNO) of 78\u2009ppb (normal range: 15\u201337\u2009ppb). Diagnosed with severe asthma.",
        "clinical_data": {
          "labs": [
            {
              "test": "Forced expiratory volume in 1s",
              "value": "1.59",
              "unit": "L"
            },
            {
              "test": "Forced vital capacity",
              "value": "64.37",
              "unit": "%"
            },
            {
              "test": "Fractional exhaled nitric oxide",
              "value": "78",
              "unit": "ppb",
              "reference_range": "15\u201337\u2009ppb",
              "flag": "abnormal"
            }
          ],
          "diagnoses": [
            {
              "code": "58845005",
              "label": "Asthma",
              "status": "active"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient received two courses of cisplatin (60 mg/m2, day 1) and tegafur/gimeracil/oteracil (TS-1) (120 mg/body, days 1-14) as first-line treatment for EGFR mutation negative, PD-L1 < 1% squamous cell carcinoma of the lung. No GCSF drugs were used during the initial chemotherapy course, and the eosinophil count did not exceed 300.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008833",
            "C3851920"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Primary tumor enlarged, diagnostic evaluation indicates progressive disease (PD) despite first-line chemotherapy with cisplatin and tegafur/gimeracil/oteracil.",
        "transition_event": {
          "trigger_type": "interpretation",
          "trigger_entities": [
            "C0032961"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Atezolizumab (1500 mg every 3 weeks) initiated as second-line therapy after progressive disease on first-line chemotherapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "Atezolizumab"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "After 19 cycles of Atezolizumab, the patient developed daily coughing, wheezing, and nocturnal symptoms. Fluticasone furanecarboxylate (200 \u03bcg)/umeclidinium bromide (62.5 \u03bcg)/vilanterol (25 \u03bcg) and a leukotriene receptor antagonist (LTRA) were administered. Eosinophil count increased from approximately 580 to 710. 30 mg prednisolone (PSL) was administered frequently as a burst dose, and continuous PSL was required.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "coughing",
            "wheezing"
          ],
          "change_type": "addition",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Respiratory function tests showed forced expiratory volume in 1s (FEV1) of 1.59\u2009L, FEV1/forced vital capacity (FVC) of 64.37% and fractional exhaled nitric oxide (FeNO) of 78\u2009ppb (normal range: 15\u201337\u2009ppb). Diagnosed with severe asthma.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "Forced expiratory volume in 1s",
            "Forced vital capacity",
            "Fractional exhaled nitric oxide"
          ],
          "change_type": "other",
          "target_domain": "lab"
        }
      }
    }
  ]
}